Integrin
All Product Categories
-
Integrin Inhibitors
(180)
View all products
-
Integrin Agonists
(5)
View all products
-
Integrin Antagonists
(68)
View all products
-
Integrin Activators
(7)
View all products
-
Integrin Modulators
(5)
View all products
-
Integrin Chemicals
(2)
View all products
-
Integrin Inducers
(2)
View all products
-
Integrin Degrader
(1)
View all products
-
Integrin Controls
(3)
View all products
-
Integrin Substrate
(1)
View all products
-
Integrin Ligands
(15)
View all products
-
Integrin Related Products (379)
Related Products (379)
-
ανβ6 Integrin ligand-2
0 ImagesCat. No.: HY-185466CAS No.: 3047235-19-5
-
RTDLDSLRTYTL TFA
0 ImagesCat. No.: HY-P10417BRTDLDSLRTYTL TFA is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL TFA binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL TFA is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL TFA can be used in the research of cancer immunotherapy and targeted drug development.
-
TAK-029
0 ImagesCat. No.: HY-19229CAS No.: 176655-58-6TAK-029 is a potent GP IIb/IIIa antagonist. TAK-029 has potent antithrombotic effects with bleeding time (BT) prolongation in arterial thrombosis models. TAK-029 can be used for the research of various arterial thrombotic diseases.
-
αvβ1 integrin-IN-2
0 ImagesCat. No.: HY-156521CAS No.: 2234874-68-9
-
FR-158999
0 ImagesCat. No.: HY-19275CAS No.: 160138-41-0FR-158999 is a potent orally active fibrinogen inhibitor. FR-158999 exhibits potent anti-platelet activities with a pIC50 of 7.50. FR-158999 can be used for antithrombotic research.
-
UR-3216
0 ImagesCat. No.: HY-122230CAS No.: 220386-65-2UR-3216 is a selective, and orally active platelet surface glycoprotein (GPIIb/IIIa) receptor antagonist. UR-3216 has the potential for cardiovascular diseases research.
-
FK 633
0 ImagesCat. No.: HY-19175CAS No.: 147865-49-4Synonyms: FR-144633FK 633 (FR-144633) is a fibrinogen inhibitor and peptide mimetic GPⅡbⅡa receptor antagonist. FK 633 has anti-platelet and anti-thrombotic effects. FK 633 inhibits ADP-, collagen-, thrombin-, and PAF-induced platelet aggregation with IC50 values of 103, 87, 98, and 239 nM, respectively.
-
MK-0668
0 ImagesCat. No.: HY-12159CAS No.: 865110-07-2MK-0668 is an amino acid-based, potent antagonist of unactivated VLA-4, with an IC50) of 0.13 nM in human whole blood. And MK-0668 exhibits IC50s of 0.19 nM in dogs, 0.21 nM in rhesus monkeys, and 0.4 nM in rats.
-
Tirofiban-d9
0 ImagesCat. No.: HY-17369BSCAS No.: 1332075-40-7Synonyms: L700462-d9; MK383-d9Tirofiban-d9 is deuterium labeled Tirofiban.
-
Elarofiban
0 ImagesCat. No.: HY-10315CAS No.: 198958-88-2Synonyms: RWJ-53308Elarofiban (RWJ-53308) is a nonpeptide, orally active antagonist for fibrinogen receptor αIIbβ3 (GPIIb/IIIa), with an IC50 of 0.15 nM. Elarofiban has the potential for platelet mediated thrombotic disorders research.
-
BGC0222
0 ImagesCat. No.: HY-P10783BGC0222 is a novel prodrug of Irinotecan (HY-16562). BGC0222, as a PEG-cRGD-conjugated Irinotecan (HY-16562) derivative, could slowly and steadily release Irinotecan (HY-16562). BGC0222 binds to αVβ3 with IC50 values of 4.25 μM (αVβ3) and 58.7 μM (αVβ5). BGC0222 possesses the property of inducing neovascularization. BGC0222 exhibits good antiproliferation activity in many tumors.
-
ICAM-1988
0 ImagesCat. No.: HY-122192CAS No.: 444169-80-6ICAM-1988 is a small molecule lymphocyte function-associated antigen-1 (LFA-1) antagonist that disrupts the LFA-1/ICAM-1 interaction and has anti-inflammatory activity.
-
LVTX-8
0 ImagesCat. No.: HY-P10988CAS No.: 2197957-07-4LVTX-8 is a peptide toxin, exacted from Lycosa vittata. LVTX-8 has potent anticancer and and anti-metastasis activities towards lung cancer with strong cytotoxicity. LVTX-8 significantly induces apoptosis and inhibits the proliferation, invasion and migration of lung cancer cells through P53 hypoxia pathways and integrin signaling. LVTX-8 significantly inhibits the tumor growth and metastasis in A549/H460 xenograft mice model.
-
XV459
0 ImagesCat. No.: HY-117177CAS No.: 170902-52-0XV459 is an orally active platelet GPIIb/IIIa receptor antagonist. XV459 blocks all agonist induced platelet aggregation by binding to platelet GPIIb/IIIa receptors. XV459 can significantly prolong occlusion time, reduce thrombus weight, and maintain blood flow. XV459 can be used for anti thrombotic research.
-
iRGD-CPT
0 ImagesCat. No.: HY-161095iRGD-CPT is a conjugate of iRGD and camptothecin that is covalently coupled through a heterobifunctional linker. iRGD-CPT has anticancer activity in vitroandin vivo. iRGD-CPT can be used for the study of colon cancer.
-
Excisanin A
0 ImagesCat. No.: HY-136699CAS No.: 78536-37-5Excisanin A is a potent anticancer agent. Excisanin A inhibits cell proliferation, migration, adhesion and invasion. Excisanin A decreases the expression of MMP-2, MMP-9, p-FAK, p-Src, integrin β1 protein. Excisanin A has the potential for the research of breast cancer.
-
Anti-CD11b Antibody (ICRF44)
0 ImagesCat. No.: HY-P991836Anti-CD11b Antibody (ICRF44) reacts with the human CD11b. Anti-CD11b Antibody (ICRF44) recognizes the α subunit of the CD11b/CD18 complex, an α/β heterodimeric surface glycoprotein on human leukocytes. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977).
-
Anti-CD11a/LFA-1α Antibody (R7-1)
0 ImagesCat. No.: HY-P990871Anti-CD11a/LFA-1α Antibody (R7-1) is a kind of mouse IgG1 chimeric antibody inhibitor, targeting to human CD11a/LFA-1α. Anti-CD11a/LFA-1α Antibody (R7-1) can neutralize LFA-1α (lymphocyte function-associated antigen 1 alpha) also known as integrin alpha L chain and CD11a. Anti-CD11a/LFA-1α Antibody (R7-1) can be used for the research of inflammation.
